WO2013027988A3 - 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 - Google Patents

트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 Download PDF

Info

Publication number
WO2013027988A3
WO2013027988A3 PCT/KR2012/006610 KR2012006610W WO2013027988A3 WO 2013027988 A3 WO2013027988 A3 WO 2013027988A3 KR 2012006610 W KR2012006610 W KR 2012006610W WO 2013027988 A3 WO2013027988 A3 WO 2013027988A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
recombinant adenovirus
treating
trans
gene
Prior art date
Application number
PCT/KR2012/006610
Other languages
English (en)
French (fr)
Other versions
WO2013027988A2 (ko
Inventor
이상진
Original Assignee
국립암센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립암센터 filed Critical 국립암센터
Priority to EP12826123.7A priority Critical patent/EP2746388A4/en
Priority to US14/239,543 priority patent/US20140286905A1/en
Priority to JP2014525948A priority patent/JP5872042B2/ja
Priority to CN201280040192.8A priority patent/CN103732739A/zh
Priority to RU2014110406/10A priority patent/RU2575620C2/ru
Priority to BR112014003423-0A priority patent/BR112014003423A2/ko
Publication of WO2013027988A2 publication Critical patent/WO2013027988A2/ko
Publication of WO2013027988A3 publication Critical patent/WO2013027988A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 암 특이 유전자에 작용하는 트랜스-스플라이싱 라이보자임-HSVtk 복합체를 코딩하는 폴리뉴클레오티드 및 암치료 유전자를 포함하는 재조합 아데노바이러스, 상기 재조합 아데노바이러스를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 상기 재조합 아데노바이러스 또는 약학 조성물을 치료를 필요로 하는 개체에 투여하는 단계를 포함하는 암을 치료하는 방법에 관한 것이다. 본 발명의 재조합 아데노바이러스는 암 특이 유전자에 작용하는 트랜스-스플라이싱 라이보자임에 의해 암 세포에 대한 선택성을 나타낼 뿐만 아니라, 암치료 유전자에 의한 상승된 항암활성을 나타내므로, 암의 효과적인 예방 및 치료에 널리 활용될 수 있을 것이다.
PCT/KR2012/006610 2011-08-19 2012-08-20 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 WO2013027988A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP12826123.7A EP2746388A4 (en) 2011-08-19 2012-08-20 RECOMBINANT ADENOVIRUS COMPRISING A RIBOZYME HAVING TRANS-SPINAGE ACTIVITY AND A GENE FOR TREATING CANCER, AND USE THEREOF
US14/239,543 US20140286905A1 (en) 2011-08-19 2012-08-20 Recombinant adenovirus comprising trans-splicing ribozyme and cancer-treating gene, and use thereof
JP2014525948A JP5872042B2 (ja) 2011-08-19 2012-08-20 トランススプライシングリボザイム及び癌治療遺伝子を含む組換えアデノウィルス及びこの用途
CN201280040192.8A CN103732739A (zh) 2011-08-19 2012-08-20 含反式剪接核糖酶及治癌基因的重组腺病毒及其用途
RU2014110406/10A RU2575620C2 (ru) 2011-08-19 2012-08-20 Рекомбинантный аденовирус, который содержит рибозим, опосредующий транс-сплайсинг, и противораковый терапевтический ген, и его применение
BR112014003423-0A BR112014003423A2 (ko) 2011-08-19 2012-08-20 Trans-splicing ribozyme and the recombinant adenoviruses and their uses, including the treatment of cancer gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110083150A KR101293620B1 (ko) 2011-08-19 2011-08-19 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
KR10-2011-0083150 2011-08-19

Publications (2)

Publication Number Publication Date
WO2013027988A2 WO2013027988A2 (ko) 2013-02-28
WO2013027988A3 true WO2013027988A3 (ko) 2013-05-16

Family

ID=47746987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006610 WO2013027988A2 (ko) 2011-08-19 2012-08-20 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도

Country Status (7)

Country Link
US (1) US20140286905A1 (ko)
EP (1) EP2746388A4 (ko)
JP (1) JP5872042B2 (ko)
KR (1) KR101293620B1 (ko)
CN (1) CN103732739A (ko)
BR (1) BR112014003423A2 (ko)
WO (1) WO2013027988A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102224965B1 (ko) * 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US10557140B2 (en) 2015-02-02 2020-02-11 Industry-Academic Cooperation Foundation, Dankook University CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof
WO2017171654A1 (en) * 2016-04-01 2017-10-05 National University Of Singapore Trans-splicing rna (tsrna)
EP3849314A4 (en) * 2018-09-14 2021-12-08 Mayo Foundation for Medical Education and Research MATERIALS AND METHODS OF TREATMENT USING ONCOLYTIC VIRUSES AND MODIFIED T CAR LYMPHOCYTES
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶
KR102396200B1 (ko) * 2020-07-24 2022-05-12 알지노믹스 주식회사 로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도
AU2022210147A1 (en) * 2021-01-25 2023-06-29 Rznomics Inc. Cancer-specific trans-splicing ribozyme expressing immune checkpoint inhibitor, and use thereor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033975T2 (de) 1989-01-23 2002-10-02 Chiron Corp Rekombinanttherapien für Infektionen und hyperproliferative Störungen
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
JP2000510449A (ja) 1996-04-10 2000-08-15 南カリフォルニア大学 増殖性硝子体網膜症に対する遺伝子治療
JP2001527517A (ja) 1996-07-26 2001-12-25 スーザン・ピー・ペリーネ 血液、ウイルス性および細胞性疾患の治療組成物
KR101034811B1 (ko) * 2008-08-25 2011-05-16 단국대학교 산학협력단 조직 특이적 프로모터와 암 특이 유전자를 타겟팅하는트랜스-스플라이싱 라이보자임을 포함하는 재조합아데노바이러스 및 이의 용도

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAN, G. ET AL.: "Cancer cell targeting with mouse TERT-specific group I intron of Tetrahymena thermophila", J. MICROBIOL. BIOTECHNOL., vol. 19, no. 9, September 2009 (2009-09-01), pages 1070 - 1076, XP055144420 *
HONG, S. H. ET AL.: "In vivo reprogramming ofhTERT by trans-splicing ribozyme to target tumor cells", MOL. THER., vol. 16, no. 1, January 2008 (2008-01-01), pages 74 - 80, XP002630648 *
JEONG, J. S. ET AL.: "Antitumor effects of systemically delivered adenovirus harboring trans- splicing ribozyme in intrahepatic colon cancer mouse model", CLIN. CANCER RES., vol. 14, no. 1, 1 January 2008 (2008-01-01), pages 281 - 290, XP055144422 *
XIAO, H. ET AL.: "Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo", CLIN. CANCER RES., vol. 13, no. 6, 15 March 2007 (2007-03-15), pages 1823 - 1830, XP055144430 *

Also Published As

Publication number Publication date
WO2013027988A2 (ko) 2013-02-28
EP2746388A2 (en) 2014-06-25
RU2014110406A (ru) 2015-09-27
JP2014524253A (ja) 2014-09-22
US20140286905A1 (en) 2014-09-25
BR112014003423A2 (ko) 2017-06-13
EP2746388A4 (en) 2015-05-13
CN103732739A (zh) 2014-04-16
JP5872042B2 (ja) 2016-03-01
KR20130020492A (ko) 2013-02-27
KR101293620B1 (ko) 2013-08-13

Similar Documents

Publication Publication Date Title
WO2013027988A3 (ko) 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
PH12014501560A1 (en) Carbamate compounds and of making and using same
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
WO2014062733A3 (en) Substituted benzene compounds
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
WO2013180537A3 (ko) 피부 투과성 펩타이드
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
EP3336100A4 (en) PEPTIDE WITH EFFECT FOR PREVENTING OR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM THEREFOR AS AN ACTIVE SUBSTANCE
PH12016501554A1 (en) Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
MX364934B (es) Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer.
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
EP3449920A4 (en) COMPOSITION USING NAPHTHOCHINONE - BASED COMPOUND AS ACTIVE AGENT FOR PREVENTING OR PREVENTING TEMPERATURE, CACHEXIA, PAIN, COGNITIVE DECONTAMINATION AND REDUCTION OF HEMATOPOETIC STEM CELLS AS SIDE EFFECTS RELATED TO A MEDICAMENTAL OIL CANCER TREATMENT
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
EP3146976A4 (en) Pharmaceutical composition for preventing or treating diabetic complications and angioedema, containing natural mixture extract as active ingredient
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
EP2910246A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH ENOBLOCK AS AN ACTIVE SUBSTANCE
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
EP3610866A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING A MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTI-CANCER DRUG AS ACTIVE SUBSTANCES
EP3698801A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES, WITH ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC MEDICINAL PRODUCT AS THE ACTIVE SUBSTANCES
EP3417869A4 (en) COMPOSITION CONTAINING RHIZOMA PHRAGMITIS EXTRACT AS AN ACTIVE INGREDIENT FOR PREVENTING, IMPROVING OR TREATING DISEASES AFFECTED BY ANTI-CANCER AGENT'S SECONDARY EFFECT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12826123

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014525948

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014110406

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14239543

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014003423

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014003423

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140213

ENP Entry into the national phase

Ref document number: 112014003423

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140213